Sarepta Slumps After FDA Says Duchenne Drug Efficacy Unproven

  • Stock down as much as 60%, biggest drop since November 2013
  • Effects `too small and variable, FDA staff says in report

Sarepta Therapeutics Inc.sank as much as 60 percent, the most since November 2013, after the U.S. Food and Drug Administration staff said its experimental drug aimed at treating Duchenne muscular dystrophy hasn’t been proven to work in clinical trials.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.